International Clinical Trials (ICT): Panthera interview

International Clinical Trials (ICT): Panthera interview – Private vs public vaccine studies, how SMOs can secure the future of UK clinical trials Panthera’s Ian Smith and Chris Dodd recently spoke to ICT about the differences in private versus public clinical trials, how speed is key in preclinical processes and how the UK can improve its …

Read more

Panthera bucks the trend and brings vaccine trials to the UK

Panthera Biopartners has become a world leader in running international vaccine studies. In the last 18 months, Panthera has run eight vaccine studies at its network of clinical trial sites across the UK on behalf of the pharma industry. Panthera’s sites are regularly first in the world or first in the UK in treating the …

Read more

CLINICAL TRIALS SPECIALIST WINS TOP INDUSTRY AWARD

Preston-based Panthera Biopartners has been named Pharma Research Centre of the Year at the Pharma Industry Awards UK 2023. The award was given in recognition of the company’s innovative SMO (Site Management Organisation) model, which focuses on speed of start-up, access to more than a million patients – many prequalified – and digitisation of contact and qualification of patients …

Read more

Management In Practice – Manchester

Our dedicated patient engagement team, comprising Chris Dodd, Erik Farish, and Sairah Yassir-Deane, had an enriching experience at the ‘Management in Practice’ event in Manchester. We had the opportunity to interact with numerous General Practitioners (GPs) from across the UK, who are keen to introduce the concept of patient engagement in clinical research to their …

Read more

Panthera contributes to Lord O’Shaughnessy’s independent review into UK clinical trials

Lord James O’Shaughnessy, former Health Minister, has been appointed by the UK government to conduct an independent review of the country’s commercial clinical trials landscape. The review will advise on how to resolve key challenges in conducting commercial clinical trials and ensure that the UK remains a global leader in the field. Lord O’Shaughnessy’s advice is expected to be published this spring.

Responsible Growth Priorities And The Hybridized Trial Of The Future.

Dr Ian Smith (Co-founder, Director and Chief Medical Officer) and Chris Dodd (Chief Commercial Officer) recently spoke to Jo Shorthouse at In Vivo to discuss the practicalities and reality of running clinical trial sites as a business, the efficiencies found with the SMO model, the challenge of patient recruitment as well as the decentralized and hybridized trial model. To listen to the …

Read more

Speeding up trial enrolment can save billions

New data show that the site management model reduces start-up times for a Phase II or Phase III clinical trial by up to nine months compared to UK public sites, representing billions in savings Panthera identifies likely patients seven months before public sector sites start planning their recruitment campaigns. The loss of nine months patent …

Read more

Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion

Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion across the UK and Western Europe Panthera Biosciences (Panthera) has secured £10 million of investment from BGF and Gresham House Ventures, the latter investing on behalf of the Baronsmead VCTs. This investment will allow Panthera to further grow its network of dedicated …

Read more